{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009312","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.828361+00:00","generated_at":"2026-06-25T21:05:44.364732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Spruce Biosciences Q1 net loss $11.8M; CAHmelia-203 25% enrolled; debt facility amended","bullets":["Net loss $11.8M in Q1 2022 vs $9.9M in Q1 2021; cash and investments $108.9M as of March 31, 2022.","CAHmelia-203 adult classic CAH study reached 25% enrollment; topline data on track for 2H 2023.","Amended SVB debt facility provides up to $10M credit line in 2022; interest rate cut 50-250 bps.","Appointed Libbie Mansell, Ph.D., as Chief Regulatory and Quality Officer in April 2022.","Tildacerfont patent portfolio expanded with two new U.S. method-of-use patents expiring 2038."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009312","json":"https://secwatch.observer/filing/0000950170-22-009312.json","markdown":"https://secwatch.observer/filing/0000950170-22-009312.md","text":"https://secwatch.observer/filing/0000950170-22-009312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022009312/0000950170-22-009312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022009312/sprb-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:05:44.364732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}